Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Personalized Prevention and Treatment in Endocrinology, Diabetes and Metabolic Diseases
share announcement

Personalized Prevention and Treatment in Endocrinology, Diabetes and Metabolic Diseases

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 425

Special Issue Editor

Dr. Grigorios Panagiotou

E-Mail Website
Guest Editor
MRC Epidemiology Unit, Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK
Interests: obesity; adipokines; myokines; personalized medicine; endocrinology

Special Issue Information

Dear Colleagues,

Recent technological advances, including the widespread application of multi-omics analyses, have paved the way for more personalized medical interventions based on individual characteristics. Indeed, in many aspects of modern medicine, including cancer treatment, clinical protocols have incorporated the use of genetic studies in order to inform decision making regarding different therapeutic options.

In diabetes and other potentially preventable metabolic diseases, the combined use of clinical data, genes, biomarkers, phenotypic characteristics, behaviors, etc., may stratify patients based on their risk of developing complications and/or the influence of decision models and algorithms on individualized treatment targets or therapies. Furthermore, with the increasing application of new real-time technologies, such as continuous glucose monitoring devices and the subsequent accumulation of day-by-day data, it is tempting to speculate that personalized preventive and/or therapeutic interventions may target individuals at both ends of the “average spectrum”, which might not fully benefit from current generic recommendations. However, this is currently more limited in daily endocrine clinical practice. Ultimately, it remains unclear whether the utilization of these novel biotechnological and molecular breakthroughs enhances or even outperforms classical methods of individualization based on more easily obtained clinical and/or biochemical parameters.

In this Special Issue of Life, I invite you to share your research on precision medicine in the field of diabetes and endocrinology, from prevention to therapies. I am hoping that this will create a forum in which ideas and suggestions regarding the maximization of these tools in our field will be presented and discussed. I warmly welcome both original research and review articles that highlight the achievements and challenges in the field, and that may further generate research ideas for future studies.

Dr. Grigorios Panagiotou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • precision prevention
  • multi-omics
  • obesity
  • diabetes and endocrinology

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 397 KiB  
Article
De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test
by Barbora Pavlikova, Martina Breburdova, Michal Krcma, Miroslav Kriz, Jan Kasparek and Zdenek Rusavy
Life 2024, 14(5), 568; https://doi.org/10.3390/life14050568 (registering DOI) - 28 Apr 2024
Viewed by 69
Abstract
Background: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the [...] Read more.
Background: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. Methods: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. Results: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (−6.4 ± 19.7 vs. −3.4 ± 22.9 mmol/mol) and weight loss (−4.6 ± 7.1 vs. −2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). Conclusions: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation. Full article
(This article belongs to the Special Issue Personalized Prevention and Treatment in Endocrinology, Diabetes and Metabolic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop